XNPT Profile
XenoPort, Inc. (XNPT) was a biopharmaceutical company focused on developing and commercializing treatments for neurological and other disorders. The company was acquired by Arbor Pharmaceuticals in 2016.
One of XenoPort's key products was Horizant, which is used to treat restless leg syndrome and postherpetic neuralgia (nerve pain following shingles). The company also had a number of other products in its pipeline targeting disorders such as migraine headaches, neuropathic pain, and spasticity associated with multiple sclerosis.
XenoPort was founded in 1999 and was headquartered in Santa Clara, California. In 2016, the company was acquired by Arbor Pharmaceuticals in a deal worth approximately $467 million.
|
